GI-270384 Study In Patients With Mild To Moderate Ulcerative Colitis

This study has been terminated.
Information provided by:
GlaxoSmithKline Identifier:
First received: April 4, 2007
Last updated: May 15, 2009
Last verified: May 2009

April 4, 2007
May 15, 2009
December 2004
Not Provided
Modified Truelove/Witts activity index for disease severity, between baseline and week 4 Endoscopic severity at 2 weeks Quality of life, as assessed by Inflammatory Bowel Disease Questionnaire, and changes on UC imaging scanning (leukocyte scan)
Same as current
Complete list of historical versions of study NCT00457171 on Archive Site
Vital signs (blood pressure, heart rate, body weight, 12-lead ECG), clinical laboratory data (haematology, clinical chemistry, urinalysis) and adverse events Cmax and AUC(0-4) of GI270384X, GI266193X and GW277348X after 14 days dosing.
Same as current
Not Provided
Not Provided
GI-270384 Study In Patients With Mild To Moderate Ulcerative Colitis
A Double-Blind, Placebo-Controlled Phase I/II Study in Patients With Mild to Moderate Ulcerative Colitis Treated With GI-270384X, an Oral ICAM-1 and E-Selectin Inhibitor
The aim of this double blind, placebo controlled, study is to evaluate activity consistent with efficacy provided by 14 days administration of GI270384X, and to provide preliminary pharmacokinetics and safety/tolerability of 14 days administration of GI270384X in patients with mild to moderate active ulcerative colitis (UC).
Not Provided
Phase 1
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Ulcerative Colitis
Drug: GI-270384
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided

Inclusion criteria:

  • Females can be of childbearing or non-childbearing potential
  • Subjects who have relapsing (relapsed = 6 weeks ago; this being at least a second episode) mild to moderate UC (score of 4 - 11 on the MTWI at Screening and with an endoscopy score of = 2). Diagnosis of UC originally must be established by sigmoidoscopy or colonoscopy, and have compatible histology.
  • As confirmed through signed informed consent, the subject must understand and be able, willing and likely to fully comply with study procedures and restrictions

Exclusion criteria:

  • Subjects with severe UC according to the MTWI (score >11) and subjects who have been in relapse for > 6 weeks.
  • Subjects are not eligible for this study if they have Crohn's Disease, proctitis (where the extent of inflammation = 15 cm), bleeding disorders, or active ulcer disease.
  • Positive stool culture for enteric pathogens (including Salmonella, Shigella, Yersinia, Aeromonas, Plesiomonas or Campylobacter).
  • Presence of Clostridium difficile toxin present or with ova or parasites as detected by microscopy.
18 Years to 55 Years
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Study Director, GSK
Not Provided
Study Director: GSK Clinical Trials, B.Sc. GlaxoSmithKline
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP